With growing concerns over blood transfusion-related complications and limited blood supplies, alternatives to transfusions have become increasingly important in perioperative care. Anesthesia providers play a key role in implementing blood-sparing strategies to minimize or avoid the need for transfusions altogether.
Blood Conservation Strategies
Techniques such as intraoperative cell salvage allow for the collection and reinfusion of the patient’s blood during surgery. This method reduces the reliance on donor blood, especially in high-blood-loss surgeries like cardiac or orthopedic procedures. Additionally, acute normovolemic hemodilution (ANH) involves the removal of a patient’s blood preoperatively, replacing it with crystalloids or colloids, and reinfusing the blood after surgery.
Clinical Example: In a patient undergoing total knee arthroplasty, the use of cell salvage has been shown to reduce blood loss and significantly decrease the need for allogeneic transfusions, improving recovery times and lowering the risk of transfusion-related complications.
Pharmacologic Alternatives
Medications like erythropoietin (EPO) can be used preoperatively to stimulate red blood cell production in patients with anemia, reducing the need for transfusions. TXA, as discussed in the pharmacological section, is also an important alternative in managing perioperative bleeding and reducing transfusion requirements.
Massive Transfusion Protocol (MTP)
The Massive Transfusion Protocol (MTP) is a critical framework used in situations of life-threatening bleeding, such as trauma, obstetric emergencies, or major surgical complications. MTP involves the rapid administration of large blood product volumes, typically 1:1:1 (red blood cells, fresh frozen plasma, and platelets), to simultaneously restore blood volume, oxygen-carrying capacity, and coagulation factors.
Key Elements of MTP:
Early Activation: MTP should be initiated as soon as a patient exhibits signs of uncontrolled bleeding, hypovolemic shock, or a need for blood products exceeding 10 units in 24 hours. Early activation ensures that blood products are available quickly and efficiently.
Balanced Resuscitation: The balanced administration of RBCs, plasma, and platelets reduces the risk of dilutional coagulopathy and promotes better hemostasis, preventing further bleeding.
Adjunctive Therapies: Adjuncts like tranexamic acid (TXA) are often administered as part of MTP to stabilize clots and minimize fibrinolysis. In addition, calcium is administered to counteract the effects of citrate in blood products, which can lead to hypocalcemia during large transfusions.
Clinical Example: In traumatic injury, early activation of MTP, combined with close monitoring of coagulation using point-of-care testing (TEG/ROTEM), can improve survival by rapidly controlling hemorrhage and restoring hemodynamic stability.
MTP is a life-saving intervention that requires seamless coordination between anesthesia providers, surgical teams, and blood banks to deliver the right products at the right time.
| Strategy | How it works | Where it is used |
|---|---|---|
| Intraoperative cell salvage | Collects and reinfuses the patient’s own blood during surgery | High-blood-loss surgery such as cardiac and orthopedic procedures; in total knee arthroplasty it reduced blood loss and the need for allogeneic transfusion |
| Acute normovolemic hemodilution (ANH) | The patient’s blood is removed preoperatively and replaced with crystalloids or colloids, then reinfused after surgery | — |
| Erythropoietin (EPO) | Stimulates red blood cell production preoperatively in patients with anemia | Given several weeks before elective surgery with anticipated blood loss, such as hip replacement |
| Topical hemostatic agents | Fibrin sealants and topical TXA control bleeding at the surgical field | Perioperative bleeding control; in one study, topical TXA in total hip arthroplasty reduced intraoperative blood loss by 30% |
